159 related articles for article (PubMed ID: 24939039)
21. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
22. [Chemotherapy induced-vomiting--a practical guide for prevention and therapy].
Jordan K; Voigt W; Schmoll HJ
Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1869-72. PubMed ID: 16915549
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
24. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Feinberg B; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
Support Care Cancer; 2012 Mar; 20(3):615-23. PubMed ID: 21761096
[TBL] [Abstract][Full Text] [Related]
25. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
26. [Prevention and control of chemotherapy-induced nausea and vomiting].
Gómez-Raposo C; Feliú-Batlle J; González-Baróna M
Med Clin (Barc); 2006 Feb; 126(4):143-51. PubMed ID: 16472500
[TBL] [Abstract][Full Text] [Related]
27. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
[TBL] [Abstract][Full Text] [Related]
29. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.
Del Favero A; Roila F; Tonato M
Drug Saf; 1993 Dec; 9(6):410-28. PubMed ID: 7510495
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
31. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
Chan A; Tan SH; Low XH; Yap KY
Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
[TBL] [Abstract][Full Text] [Related]
32. Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients.
Sherani F; Boston C; Mba N
Curr Oncol Rep; 2019 Aug; 21(10):89. PubMed ID: 31418119
[TBL] [Abstract][Full Text] [Related]
33. Management of chemotherapy-induced nausea and vomiting.
Dewan P; Singhal S; Harit D
Indian Pediatr; 2010 Feb; 47(2):149-55. PubMed ID: 20228428
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Lorusso V; Giampaglia M; Petrucelli L; Saracino V; Perrone T; Gnoni A
Support Care Cancer; 2012 Dec; 20(12):3241-6. PubMed ID: 22534864
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of antiemetic therapy after the administration of high-dose antineoplastic agents.
Trovato JA; Stull DM; Finley RS
Am J Health Syst Pharm; 1998 Jun; 55(12):1269-74. PubMed ID: 9640466
[TBL] [Abstract][Full Text] [Related]
38. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Momper JD; Heinrichs MT; Krudys K; Griebel D; Kumar S; Kim I; Mehrotra N; Mulberg AE; Garimella N; Nelson R; Reaman G; Sinha V; Yao L; Zineh I; Burckart G; Sachs H; Mulugeta Y
J Clin Pharmacol; 2020 Jun; 60(6):775-784. PubMed ID: 31967340
[TBL] [Abstract][Full Text] [Related]
39. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.
Mahendraratnam N; Farley JF; Basch E; Proctor A; Wheeler SB; Dusetzina SB
Support Care Cancer; 2019 Dec; 27(12):4525-4534. PubMed ID: 30915567
[TBL] [Abstract][Full Text] [Related]
40. Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy.
Falkson CI; Falkson HC
Oncology; 1995; 52(5):427-31. PubMed ID: 7637962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
